MORVEN EDWARDS to Antibodies, Bacterial
This is a "connection" page, showing publications MORVEN EDWARDS has written about Antibodies, Bacterial.
Connection Strength
1.480
-
Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine. 2012 Jun 13; 30(28):4123-6.
Score: 0.326
-
Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 2007 Jan 02; 25(1):55-63.
Score: 0.219
-
Antibodies to type III group B streptococcal polysaccharide in breast milk. Pediatr Infect Dis J. 2004 Oct; 23(10):961-3.
Score: 0.193
-
Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 05; 19(5):e162-e171.
Score: 0.130
-
Immune Responses to Invasive Group B Streptococcal Disease in Adults. Emerg Infect Dis. 2016 11; 22(11):1877-1883.
Score: 0.112
-
Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014 Mar 01; 209(5):781-8.
Score: 0.090
-
Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation. Vaccine. 2009 Jul 16; 27(33):4452-6.
Score: 0.067
-
Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine. 2008 Jan 24; 26(4):502-8.
Score: 0.060
-
Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. J Infect Dis. 2007 Feb 01; 195(3):353-6.
Score: 0.056
-
Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis. 2005 Feb 01; 40(3):352-7.
Score: 0.049
-
Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis. 2004 Aug 01; 190(3):558-64.
Score: 0.047
-
Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003 Jul 01; 188(1):66-73.
Score: 0.044
-
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun. 2002 Apr; 70(4):1724-38.
Score: 0.041
-
A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III. Clin Infect Dis. 2019 05 30; 68(12):2079-2086.
Score: 0.033
-
Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004 Mar 15; 189(6):1103-12.
Score: 0.012